Listed by the USPTO as REYNOLDS, FRED H
Tech Center 1600 • Art Units: 1613 1645 1654 1658 1675
This examiner grants 33% of resolved cases
REYNOLDS, FRED H is assigned to tech center 1600 and art unit 1613. The record includes 847 resolved cases, a 32.9% allowance rate, and a median of 1095 days to allowance. The interview lift is 39.3%, a strong positive association that distinguishes interview-associated outcomes from the lower overall allowance result.
The listed companies are The Regents of the University of California, Board of Regents of the University of Texas System, and Korea Research Institute of Bioscience and Biotechnology. The listed firms are Clark+Elbing LLP, SUGHRUE MION, PLLC, and FBT Gibbons LLP. Practitioners should give interviews significant strategic attention while also preparing for substantive written prosecution. The case volume supports using the measured pattern as a meaningful planning signal.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18338700 | METHOD FOR PRODUCING PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND CONDENSED POLYCYCLIC COMPOUND | Non-Final OA | FUJIFILM Corporation |
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | Final Rejection | University of Massachusetts |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | Non-Final OA | Novo Nordisk A/S |
| 17747952 | SOLID PHASE PEPTIDE SYNTHESIS METHODS AND ASSOCIATED SYSTEMS | Non-Final OA | Massachusetts Institute of Technology |
| 18030433 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18253231 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA | Non-Final OA | The Johns Hopkins University |
| 18259092 | METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS | Non-Final OA | University of Rochester |
| 18030876 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | Non-Final OA | The General Hospital Corporation |
| 18252069 | METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS | Final Rejection | The Regents of the University of California |
| 17597925 | ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17006591 | PROTEASE SENSITIVE GVPC AND RELATED GAS VESICLE GENE CLUSTERS, EXPRESSION SYSTEMS, CONSTRUCTS, VECTORS, GENETIC CIRCUITS, CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING | Final Rejection | California Institute of Technology |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17608025 | METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATING THERAPIES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17586258 | MUTANTS AND DRUG CONJUGATES OF R-SPONDINS AND USE THEREOF | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 17780843 | NEONATAL FIBRIN SCAFFOLDS FOR PROMOTING WOUND HEALING | Final Rejection | North Carolina State University |
| 17251079 | NON-VITAL WHEAT PROTEIN AND ITS PRODUCTION PROCESS | Final Rejection | ROQUETTE FRERES |
| 18576993 | PEPTIDE AND COMPOSITION | Non-Final OA | OSAKA UNIVERSITY |
| 17607334 | CHIMERIC PROTEINS AND METHODS TO SCREEN FOR COMPOUNDS AND LIGANDS BINDING TO GPCRS | Final Rejection | CONFO THERAPEUTICS N.V. |
| 18548545 | ALPHA-1 ANTITRYPSIN DOSING REGIMEN | Non-Final OA | GRIFOLS WORLDWIDE OPERATIONS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy32.9% of resolved applications examined by Fred H Reynolds were allowed (847 resolved cases), compared with 34.0% across Art Unit 1613 over the last five years.
This examiner's interview lift is +39.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Fred H Reynolds took 1,095 days on average from filing to allowance.
Fred H Reynolds examines applications in Art Unit 1613 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
